Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rifabutin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 3/20 | 0.72 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.72 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.72 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.72 |
| ▸ | ABCC2 | Q92887 | 2/20 | 0.72 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.72 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.70 |
| ▸ | MAPT | P10636 | 3/20 | 0.70 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.70 |
| ▸ | TSHR | P16473 | 2/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.70 |
| ▸ | POLB | P06746 | 1/20 | 0.70 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.70 |
| ▸ | SLCO2B1 | O94956 | 2/20 | 0.59 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.59 |
| ▸ | SLCO1A2 | P46721 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rifabutin SCHEMBL1813946 | 1.00 | ABCB11 (0.72) | ABCB11CHRM1PTGS1ABCC4ABCC2 | |
| Rifabutin SCHEMBL17705915 | 1.00 | ABCB11 (0.72) | ABCB11CHRM1PTGS1ABCC4ABCC2 | |
| Rifabutin SCHEMBL36044 | 1.00 | ABCB11 (0.72) | ABCB11CHRM1PTGS1ABCC4ABCC2 | |
| Rifabutin SCHEMBL28325467 | 1.00 | ABCB11 (0.72) | ABCB11CHRM1PTGS1ABCC4ABCC2 | |
| Rifabutin SCHEMBL41044 | 1.00 | ABCB11 (0.72) | ABCB11CHRM1PTGS1ABCC4ABCC2 | |
| Rifabutin SCHEMBL138130 | 1.00 | ABCB11 (0.72) | ABCB11CHRM1PTGS1ABCC4ABCC2 | |
| Rifabutin SCHEMBL36043 | 1.00 | ABCB11 (0.72) | ABCB11CHRM1PTGS1ABCC4ABCC2 | |
| Rifabutin SCHEMBL7778399 | 0.98 | ABCB11 (0.70) | ABCB11CHRM1PTGS1ABCC4ABCC2 | |
| Rifabutin SCHEMBL173466 | 0.98 | ABCB11 (0.70) | ABCB11CHRM1PTGS1ABCC4ABCC2 | |
| Rifabutin SCHEMBL155626 | 0.98 | ABCB11 (0.70) | ABCB11CHRM1PTGS1ABCC4ABCC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250387381-A1 | COMPOSITIONS AND METHODS FOR ENHANCED DRUG LOADING OF LONG-ACTING IN SITU FORMING IMPLANTS AND USES THEREOF | UNIV NORTH CAROLINA CHAPEL HILL (US) | 2025-12-25 | — | — | US | claimed |
| EP-4426729-A1 | SPECIFIC CONJUGATION FOR AN ANTIBODY-DRUG CONJUGATE | Hangzhou Dac Biotech Co., Ltd. (CN) | 2024-09-11 | — | — | EP | claimed |
| US-20240293351-A1 | METHODS OF ADMINISTERING SYNTHETIC TRITERPENOIDS | Reata Pharmaceuticals Holdings, LLC (US) | 2024-09-05 | — | — | US | claimed |
| EP-4028001-B1 | RIFABUTIN TREATMENT METHODS, USES, AND COMPOSITIONS | BioVersys AG (CH) | 2024-04-10 | — | — | EP | claimed |
| EP-4259155-A1 | SYNTHETIC TRITERPENOIDS FOR USE IN THERAPY | Reata Pharmaceuticals Holdings, LLC (US) | 2023-10-18 | — | — | EP | claimed |
| CN-116650492-A | Administration of antibiotic compounds for the treatment of streptococcal infections to treat psoriasis | 消化系统疾病中心 | 2023-08-29 | — | — | CN | claimed |
| WO-2023154520-A1 | COMPOSITIONS AND METHODS FOR ENHANCED DRUG LOADING OF LONG-ACTING IN SITU FORMING IMPLANTS AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2023-08-17 | — | — | WO | claimed |
| WO-2023078273-A1 | SPECIFIC CONJUGATION FOR AN ANTIBODY-DRUG CONJUGATE | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-05-11 | — | — | WO | claimed |
| WO-2022126129-A1 | SYNTHETIC TRITERPENOIDS FOR USE IN THERAPY | REATA PHARMACEUTICALS, INC. (US) | 2022-06-16 | — | — | WO | claimed |
| EP-3986463-A1 | A CONJUGATE OF A CYTOTOXIC AGENT TO A CELL BINDING MOLECULE WITH BRANCHED LINKERS | Hangzhou Dac Biotech Co., Ltd. (CN) | 2022-04-27 | — | — | EP | claimed |
| EP-4748448-A2 | USE OF MARIBAVIR FOR THE TREATMENT OF AND TREATMENT REGIMENS THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2026-05-27 | — | — | EP | disclosed |
| EP-4748371-A1 | RIFABUTIN COMPOSITIONS AND METHOD OF MAKING | BIOVERSYS AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| EP-4731194-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP Technologies, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20260109712-A1 | RIFAMYCINS FOR NONTUBERCULOUS MYCOBACTERIA | UNIV MINNESOTA (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4433065-B1 | USE OF MARIBAVIR FOR THE TREATMENT OF CYTOMEGALOVIRUS INFECTION AND TREATMENT REGIMENS THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2026-03-11 | — | — | EP | disclosed |
| US-20220062188-A1 | ALL-IN-ONE FIXED-DOSE COMBINATION FOR TREATING HELICOBACTER PYLORI INFECTION | REDHILL BIOPHARMA LTD. (IL) | 2022-03-03 | — | — | US | disclosed |
| CN-113975274-A | Cyclofused thiazoline 2-pyridones, method for the production thereof and use thereof for treating and/or preventing tuberculosis | 快尔生物技术公司 | 2022-01-28 | — | — | CN | disclosed |
| US-11207305-B2 | Antibiotic combination therapies | BioVersys AG (CH) | 2021-12-28 | — | — | US | disclosed |
| US-20210077470-A1 | RIFABUTIN TREATMENT METHODS, USES, AND COMPOSITIONS | BioVersys AG (CH) | 2021-03-18 | — | — | US | disclosed |
| US-20210077472-A1 | ANTIBIOTIC COMBINATION THERAPIES | BioVersys AG (CH) | 2021-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240293351-A1 | METHODS OF ADMINISTERING SYNTHETIC TRITERPENOIDS | CYP4A11, CYP3A4, CYP11B1 | ABCB11 163/4885CHRM1 1789/4885PTGS1 1078/4885 |
| US-20210077470-A1 | RIFABUTIN TREATMENT METHODS, USES, AND COMPOSITIONS | RIF1, TREH, IL6 | ABCB11 44/4885CHRM1 4701/4885PTGS1 2792/4885 |
| US-20260109712-A1 | RIFAMYCINS FOR NONTUBERCULOUS MYCOBACTERIA | RIF1, MRPL21, NRDC | ABCB11 308/4885CHRM1 531/4885PTGS1 4232/4885 |
| US-11207305-B2 | Antibiotic combination therapies | ATF4, AMPD3, CFB | ABCB11 68/4885CHRM1 4114/4885PTGS1 3660/4885 |
| US-20210077472-A1 | ANTIBIOTIC COMBINATION THERAPIES | ATF4, AMPD3, CFB | ABCB11 68/4885CHRM1 4114/4885PTGS1 3660/4885 |
| US-20250387381-A1 | COMPOSITIONS AND METHODS FOR ENHANCED DRUG LOADING OF LONG-ACTING IN SITU FORMING IMPLANTS AND USES THEREOF | VEGFA, ABCB11, PGR | ABCB11 2/4885CHRM1 1403/4885PTGS1 691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.